SK Chemicals’ hemophilia therapy ‘AFSTYLA’ on the way to enter EU

Published: 2016-11-17 09:15:10

Updated: 2016-11-17 10:56:13

On the 15^th, SK Chemicals(President Man-Hoon Park) announced the hemophilia treatment ‘AFSTYLA’ was recommended by the Committee for Medicinal Products for Human Use(CHMP), an affiliated organization of the European Medicines Agency(EMA), to be approved to commercialize.

Therefore, AFSTYLA has took a huge step to enter the EU market for the first time as a biomedicine developed by Korean techn...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.